Lightbridge (NASDAQ:LTBR) reported quarterly losses of $(0.14) per share. This is a 48.15 percent increase over losses of $(0.27) per share from the same period last year.
Credit Suisse Maintains Outperform on Prometheus Biosciences, Raises Price Target to $142
Credit Suisse analyst Tiago Fauth maintains Prometheus Biosciences (NASDAQ:RXDX) with a Outperform and raises the price target from $59 to $142.